The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).
 
Shiao-Pei S. Weathers
Research Funding - Genentech/Roche (Inst); Mundipharma (Inst)
 
Carlos Kamiya-Matsuoka
No Relationships to Disclose
 
Rebecca A. Harrison
No Relationships to Disclose
 
Diane D. Liu
No Relationships to Disclose
 
Shannon Dervin
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Travel, Accommodations, Expenses - Genentech/Roche
 
Cindy Yun
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Monica Elena Loghin
No Relationships to Disclose
 
Marta Penas-Prado
No Relationships to Disclose
 
Nazanin Majd
No Relationships to Disclose
 
W. K. Alfred Yung
Stock and Other Ownership Interests - DNATrix; Quadriga
Honoraria - DNAtrix
Consulting or Advisory Role - DNAtrix; Quadriga
Patents, Royalties, Other Intellectual Property - DNATrix
 
Barbara Jane O'Brien
Honoraria - Seagen
 
John Frederick De Groot
Employment - ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; Agios; AstraZeneca; Blue Earth Diagnostics; Boston Biomedical; CarThera; Deciphera; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; GenomiCare; GW Pharmaceuticals; Insys Therapeutics; Kadmon; Kairos Ventures; KIYATEC; Merck; Mundipharma Research; Novogen; Vascular Biogenics
Research Funding - Deciphera; EMD Serono; Lilly; Mundipharma; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - AstraZeneca - Research Support; Deciphera Pharmaceuticals - Research Support; Eli Lilly - Research Support; EMD-Serono - Research Support; Novartis - Research Support; Sanofi-Aventis - Research Support
Travel, Accommodations, Expenses - Blue Earth Diagnostics